LIMK1 Inhibitors
1 drugsAbout LIMK1
LIMK1, or LIM Kinase 1, is a protein kinase that regulates cellular processes through phosphorylation. Aberrant kinase activity is often implicated in disease, making them attractive targets for therapeutic intervention.
LIMK1 is a therapeutic target in oncology, though there is currently no genetic evidence data available linking it to specific diseases. The rationale for targeting this kinase may stem from its role in cellular signaling pathways known to be dysregulated in cancer.
LIMK1 is targeted by one FDA-approved drug, TAFINLAR (Novartis), a small molecule with 4 indications in oncology. TAFINLAR was first approved in 2013.
Top LIMK1 Drugs
Novartis is the only company with an approved drug targeting LIMK1.
The single-player competitive landscape suggests high barriers to entry or limited perceived market opportunity.
LIMK1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets LIMK1, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or PROTACs.
LIMK1 Clinical Trials 93 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on LIMK1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 33 | 12 | 13 | 6 | 48% |
| Phase 2 | 49 | 15 | 12 | 22 | 56% |
| Phase 3 | 8 | 4 | 1 | 3 | 80% |
| Phase 4 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
LIMK1 Drug Approval Timeline (2013 - 2013)
TAFINLAR was first approved in 2013 and remains the only approved drug.
The stagnant approval timeline indicates potential target saturation or challenges in developing new LIMK1-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 47 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on LIMK1. A trial counts if an approved drug acting on LIMK1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.